Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144412 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL476790 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL6373800 | 0.98 | ALDH1A1 (0.50) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL2203097 | 0.98 | ALDH1A1 (0.50) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL476789 | 0.98 | ALDH1A1 (0.50) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL4591411 | 0.93 | KCNA5 (0.49) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL1144253 | 0.93 | KCNA5 (0.49) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Tartaric Acid SCHEMBL29904324 | 0.92 | ALDH1A1 (0.46) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL2299744 | 0.90 | PTGS2 (0.46) | ALDH1A1KCNA5KMT2ACYP3A4 | |
| SCHEMBL27575989 | 0.88 | KMT2A (0.44) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| CN-117642396-A | Alpha V beta 6 and alpha V beta 1 integrin inhibitors and uses thereof | 戴斯分子SV有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4304716-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | Dice Molecules Sv, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192545-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3521274-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-01 | — | — | US | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003091212-A1 | CINNAMIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003080574-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| CN-1437599-A | Tropane derivatives for use in therapy | PFIZER LTD (US) | 2003-08-20 | — | — | CN | disclosed |
| CN-1331691-A | Piperidines as CCR5 modulators | PFIZER LTD (US) | 2002-01-16 | — | — | CN | disclosed |
| CN-1331591-A | Piperidines as CCR5 modulators | PFIZER LTD (US) | 2002-01-16 | — | — | CN | disclosed |
| CN-1069316-C | Substituted 5-ring heterocycles, their preparation and their use | HOECHST AG (DE) | 2001-08-08 | — | — | CN | disclosed |
| EP-1013276-A1 | Aminoazacycloalkanes as CCR5 modulators | PFIZER INC. (US) | 2000-06-28 | — | — | EP | disclosed |
| CN-1134696-A | Substituted 5-membered heterocycles, process for their preparation and their use | CASSELLA FARBWERKE MAINKUR AG (DE) | 1996-10-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | ALDH1A1 858/4885KCNA5 587/4885KMT2A 3333/4885 |
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | PRMT3, GRIN3A, RAMP3 | ALDH1A1 3474/4885KCNA5 3103/4885KMT2A 1662/4885 |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | PRMT3, GRIN3A, RAMP3 | ALDH1A1 3474/4885KCNA5 3103/4885KMT2A 1662/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | ALDH1A1 3596/4885KCNA5 2689/4885KMT2A 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.